413 results about "Gentamicin" patented technology

The present invention provides an adipose tissue-derived mesenchymal stem cell amplification culture method, which comprises: preparing a suspension containing adipose tissue-derived mesenchymal stem cells with an adipose-derived stem cell culture medium, and inoculating the suspension into a stem cell culture device being subjected to a fibronectin coating treatment to carry out amplification culture. According to the present invention, the solid-phase support for growth and adhesion of the fibronectin-coated adipose-derived mesenchymal stem cells is used, and the synergetic screening culture of the low-concentration fetal bovine serum and the high-concentration gentamicin is used, such that the adipose tissue-derived mesenchymal stem cells can be amplified by 400-500 times within two weeks, the purity is high, and the adipose tissue-derived mesenchymal stem cells can be subjected to directional induction differentiation to obtain the adipose tissue.

The invention relates to a culture medium for a normal epithelial cell of a human or mammal, primary separation culture, subculture, 3D gas-liquid culture and 3D matrigel culture methods, the normal epithelial cell generated by using the culture medium and the culture methods and application of the normal epithelial cell to a toxicological evaluation system. The culture medium is prepared by mixing DMEM and Ham's F-12NUTRIENT MIX according to the volume ratio of 3:1 and also adding 4-6% of fetal calf serum, 1-3nM triiodothyronine, 0.4-0.65% of insulin-transferrin-selenium reagent, 4-6mu g/ml transferrin, 9-11ng/mL epidermal growth factors, 0.3-0.5mu g/mL hydrocortisone, 0.5-1.5nM cholera toxin, 0.4-0.6mu g/mL amphoterrible B, 35-45mu g/mL gentamicin, 45-55nM calpeptin, 35-45ng/ml recombinant human IL-1RA and 3mu g/ml recombinant human R-Spondin-1. The culture medium disclosed by the invention can be used for carrying out separation culture or subculture on the normal epithelial cell of the human or the mammal and any other various tissue source, rapidly proliferating the normal epithelial cell in vitro and establishing a cell line; and the normal epithelial cell is a normal diploid cell and is applied to the toxicological evaluation system of the human or the mammal.

The present invention is directed to a pharmaceutical composition comprising a therapeutically effective amount of misoprostol and an effective amount of an antibiotic. A suitable antibiotic is selected from the group consisting of doxycycline, gentamicin, tobramicin, ciprofloxacin, clindamycin, clarithromycin, azithromycin and metronidazole. Preferred antibiotics are doxycycline and ciprofloxacin. More preferably, the antibiotic is doxycycline. In its second aspect, the present invention is directed to a method for treating periodontal disease in a mammalian patient comprising administering to a mammalian patient in need of such treatment a therapeutically effective amount of misoprostol and an effective amount of an antibiotic. Typically, the mammalian patient is a human.

The invention discloses a treatment method of antibiotic fermenting bacterial residues. The treatment method comprises the following steps: uniformly mixing the fermenting bacterial residues of lincomycin hydrochloride and gentamicin with water, and preparing a suspension; performing anaerobic fermentation treatment on the suspension. The treatment method is an efficient fermentation treatment process of the fermenting bacterial residues of lincomycin hydrochloride and gentamicin and belongs to the technical field of resource utilization of the bacterial residues. By adopting the method disclosed by the invention, the toxicity, the harm and an inhibition effect of residual antibiotics to fermenting bacteria in an anaerobic fermentation process of the traditional antibiotic bacterial residues are overcome, the problems of blockage, short flow and the like which are produced when a traditional filler is fed are simultaneously avoided, the biomass of a hydrolysis acidification pool and an L-fermentation tank is ensured, the gas production is improved and the method further has the advantages of low treatment cost, easiness in control of operation process, high load of a reactor matched with the method, small occupied area and the like.

The invention relates to an antibacterial bone formation-promoting composite functional porous orthopaedic implant and a preparation method. The preparation method comprises the following steps: (1) preparing a porous orthopaedic implant by utilizing a 3D printing technology; (2) carrying out surface treatment on the porous orthopaedic implant by utilizing a micro-arc oxidation method, and covering the surface of the porous orthopaedic implant with a micro-arc oxidation coating containing calcium and phosphorus elements; (3) soaking the implant treated by the step (2) into 2-5mg/mL dopamine hydrochloride solution, and vibrating for 20-24 hours at the constant temperature of 30-45 DEG C; and (4) by taking deionized water or distilled water as a solvent, adding heparin sodium and preparing aheparin sodium solution with the concentration of 1-5mg/mL, then by taking the heparin sodium solution as a solvent, adding gentamicin and preparing a gentamicin solution with the concentration of 1-5mg/mL; and soaking the implant treated by the step (3) into the gentamicin solution, and vibrating for 4-10 hours at the constant temperature of 30-45 DEG C, so that the implant is obtained.

The invention discloses an artificial diet for predative natural enemy insect-true bugs. The feeding prescription comprises 2-4g of soybean flour, 15-25g of raw pig liver, 24-50g of egg yolk, 30-50ml of water, 7-12g of cane sugar, 0.1-0.3g of vitamine C, 20-50mg of compound vitamin B, and 2-4mg of gentamicin. Each biological indicator or parameter of the stinkbugs fed by the feed disclosed by the invention is mostly the same as the parameter of the stinkbugs fed by tussah pupas; the pre-oviposition period of female fed by the artificial diet is a little longer than that of the female fed by the tussah pupas, and about 4 days longer than that of the female fed by the tussah pupas; however, the feed prescription disclosed by the invention is low in cost and simple in preparation; characters of the fed stinkbugs are similar with those of the stinkbugs fed by the tussah pupas, and the artificial diet is suitable for generalization and application in the industry.

A method of treating prostate cancer in a living mammal includes local administration of a composition that includes a therapeutically effective concentration of collagenase. In one embodiment, a method of treating prostate cancer in a living mammal includes local administration of a composition that includes a therapeutically effective concentration of collagenase and at least one of a glycosidase, a protease, a nuclease, a lipase, an esterase, a plasminogen activator, a streptokinase, and combinations thereof. Preferably a glycosidase, such as, for example, hyaluronidase, is administered. Compositions used in methods for treating prostate cancer can also include or be administered with calcium ions, a nonionic surfactant, such as, for example, Triton® X-100, and an antibiotic, such as, for example, gentamicin. Another method of treating prostate cancer in a living mammal includes activating PSA in vivo by, for example, locally administering calcium ions.

The invention discloses a novel frozen semen diluent used for improving the freeze-thaw quality and fertilization rate of frozen bovine semen and a preparation method thereof. Every 100ml of the prepared frozen semen diluent contains 0.9-1.2g of sodium citrate, 3-5g of sucrose, 18-22ml of yelk, 4-7ml of glycerin, 6-9mg of vitamin E, 500-700mg of vitamin C, 35mg of spectinomycin and 80 thousand units of gentamicin. The invention adds VE and VC into the semen diluent for the first time, so as to increase the motility rate and acrosome integrity of the frozen sperm as well as the activity of antioxidant enzyme in seminal plasma, thus improving the quality and fertilization rate of the freeze-thaw sperm.

A Bacillus strain characterized by (i): sensitivity for ampicillin, vancomycin, gentamicin, kanamycin, streptomycin, erythromycin, clindamycin, tetracycline and chloramphenicol; (ii) antimicrobial activity against E. coli and Clostridium perfringens; and (iii) a sporulation percentage of at least 80 when measured after 2 days of incubation. The invention further relates to a method for selecting such strains. Many of the identified strains according to the invention are of the species Bacillus amyloliquefaciens. Some of the Bacillus amyloliquefaciens were further identified as Bacillus amyloliquefaciens subsp. amyloliquefaciens whereas others were identified as amyloliquefaciens subsp. plantarum. A Bacillus strain of the invention may be used as a feed additive to animal feed where it has a probiotic effect.

The present invention comprises compositions for treating diseases caused by nonsense mutations, including dipeptide antibiotics of Formula (I) shown below, such as negamycin. Unlike aminoglycoside antibiotics such as gentamicin, dipeptide antibiotics can induce the expression of mature proteins by readthrough nonsense mutations without generating serious side effects.

The invention discloses a medical composite alginate dressing containing antibacterial drugs and a preparation method thereof. In parts by weight, the medical composite alginate dressing comprises the following components: 50-99.9 parts of alginate and 0.05-10 parts of antibacterial drugs, The antibacterial drug is selected from gentamicin or its salt, neomycin or its salt, amikacin or its salt, fusidic acid or its salt, kanamycin or its salt, polycresol , mupirocin, sulfamethonium or its salt and clindamycin or its salt at least one. The medical composite alginate dressing of the present invention has strong ability to absorb exudate, has good water vapor transmission rate, can be biodegraded and has good biocompatibility, does not adhere to the wound and can quickly form gel after absorbing wound exudate , has strong moisturizing properties, can effectively promote wound healing, shorten wound repair time, can effectively prevent or treat sensitive bacterial infections, and can be widely used in acute and chronic wounds with exudate.

The invention discloses Pseudomonas nitroreducens and application thereof, belonging to the field of environmental microorganism. The Pseudomonas nitroreducens CQ1 of the invention is derived from thesewage of oxidation ponds in the sewage treatment system of Beijing Yanshan Petrochemical Co., Ltd., and obtained by enriching, separating and purifying. The Pseudomonas nitroreducens CQ1 is culturedand collected in the China General Microbiological Culture Collection Center (hereinafter referred to as CGMCC) with the collection number being CGMCC No.3159. The invention further discloses the application of Pseudomonas nitroreducens in the biodegradation of quinoline or derivatives thereof. Quinoline or derivatives thereof with the concentration reaching 700mg/L can be degraded by Pseudomonasnitroreducens of the invention, and the degradability can reach 100% after treating for 72h. Moreover, the Pseudomonas nitroreducens CQ1 of the invention is sensitive to kanamycin sulfate, tetracycline and gentamicin and does not carry plasmids.

The invention provides a flushing fluid for surgery, which comprises solute and solvent, wherein the solute is one or two selected from cellulose glycollic ether, carboxymethyl chitosan or carboxymethyl chitosan, the solvent being water for injection, physiological saline solution, sodium chloride flushing fluid, mannitol flushing fluid, glucose flushing fluid, chlorhexidine flushing fluid, gentamicin physiological saline flushing fluid, active iodine flushing fluid, benzalkonium bromide flushing fluid, aminoacetic acid flushing fluid, metronidazole flushing fluid or physiological equilibrium liquid comprising phosphates cushioning liquid, NaHCO3, sodium gluconate and mannitol.

The invention relates to a neural stem cells medium and a method for performing human neural stem cells in-vitro long-term culture and amplification by using the neural stem cells medium. The neural stem cells medium comprises the following ingredients by weight proportion: 100-1000 micrograms of heparin sodium, 10-100 micrograms of vitamin E, 5-50 milligrams of insulin human recombinant, 0.5-5 milligrams of putrescine, 2-10 micrograms of sodium selenite, 2-10 milligrams of human transferrin, 2-10 micrograms of progestin, 300 milligrams of L-glutamine, 5.9 grams of 2-[4-(2-Hydroxyethyl)-1-piperazine]ethanesulfonic acid, 10-100 micrograms of recombinant human epidermal growth factors, 10-100 micrograms of recombinant human basic fibroblast growth factors, 20-200 milligrams of vitamin C glucoside and 40,000-400,000 IU (international unit) of gentamicin. By the neural stem cells medium, the technical problems that human neural stem cells are easy to differentiate when cultured in vitro and long-term culture and amplification are difficult to implement are solved.

The invention relates to preparation and storage of umbilical cord-mesenchymal stem cells (UC-MSCs) used in clinical therapy. The preparation method of the UC-MSCs comprises the following steps: cleaning an umbilical cord and cutting the umbilical cord into granules; putting the granules in physiological saline containing 2 percent gentamicin; carrying out centrifugation, suspension and centrifugation; carrying out cultivation for 10 days; carrying out passage in the proportion of 1:3 to between fourth and fifth generation, and obtaining a great amount of mesenchymal stem cells; and finally, putting the mesenchymal stem cells in liquid nitrogen for storage after adding freezing medium and keeping the freezing temperature of the liquid nitrogen at 196 DEG C below zero.

The invention relates to placenta preserving fluid with pH value of 7.33-7.83; the placenta preserving fluid per 1,000ml contains 10-15mmol of potassium dihydrogen phosphate, 30-40mmol of sodium chloride, 40-50mmol of potassium chloride, 8-10mmol of magnesium sulfate, 70-100mmol of histidine, 1.5-2.0mmol of allopurinol, 3mmol of reduced glutathione, 1-8ml of 2-mercaptoethanol, 8-10mmol of adenosine, 1,000,00-1,000,000U of penicillin, 60-100mg of streptomycin and 50-70mg of gentamicin. The placenta preserving fluid can store the delivered placenta for a long time, prevent from reduction of cell activity and control the bacteria contamination rate of the placenta to be in a low level.

The present invention relates to the field of bacteriology. In particular, the present invention provides compositions (e.g., comprising a lantibiotic and mupirocin or gentamicin) and methods of treating (e.g., killing or inhibiting growth of) bacteria. For example, the present invention provides pharmaceutical compounds (e.g., comprising a lantibiotic and mupirocin or gentamicin) and methods of using the same in research, therapeutic and drug screening applications.

The invention relates to an NK cell in-vitro amplification culture medium combination and a culture method. The culture medium combination comprises a base culture medium, an induced culture medium, a proliferation culture medium and an activated adaptive culture medium, wherein the base culture medium is prepared from the following components: an RPMI-1640 (Roswell Park Memorial Institute-1640) culture medium, a GT-T551 culture medium, gentamicin and BSA (Bovine Serum Albumin); the induced culture medium is prepared from the following components: the RPMI-1640 culture medium, the GT-T551 culture medium, the BSA, lentinan, ganoderma lucidum polysaccharides, tea polyphenols, allicin and paclitaxel; the proliferation culture medium is prepared from the following components: the RPMI-1640 culture medium, the GT-T551 culture medium, the BSA and interleukins; and the activated adaptive culture medium is prepared from the following components: the RPMI-1640 culture medium, the GT-T551 culture medium, insulin, transferrin and glutamine. According to the technical scheme, the quantity of NK cells cultured by the NK cell in-vitro amplification culture medium combination and the method is more, and the NK cells also have higher activity in clinical treatment.

The invention provides a preparation method of long-acting boar semen diluting powder. According to the method, 26-36 g of glucose, 3-7 g of dry chicken egg-yolk powder, 3-6 g of sodium citrate, 1.5-2.5 g of aminoacetic acid, 1.0-2.0 g of disodium hydrogen phosphate, 1.0-2.0 g of ethylene diamine tetraacetic acid disodium, 2.0-4.0 g of potassium sorbate, 1.0-2.0 g of calcium propionate, and 0.005-0.02 g of gentamicin powder are taken; the powdery raw materials taken according to the previous quantities are evenly mixed together so that the boar semen diluting powder is obtained. The preparation method of the dry chicken egg-yolk powder comprises the following steps: cooking a fresh chicken egg, taking out the egg yolk and drying the egg yolk to obtain dry chicken egg-yolk powder with the moisture content of 1-10%. The nutrient solution for diluting boar semen prepared by the raw materials provided in the method and distilled water contains a nutritional agent, a diluting agent, a buffering agent, a pH regulator and an antibiotic, as well as a preservative and a bacteriostatic agent, and can be preserved for 0-12 days under the condition of a constant temperature ranging from 15 to 20 DEG C.

The invention provides an enzyme linked immune regent box to detect gentamycin. It includes: the enzyme labeled board which encrusts the encrusting substance, the enzyme marker, the special antibody for the gentamycin (when the antigen is on enzyme labeled board and the enzyme marker is the enzyme labeled antiantibody or the antiantibody is in the enzyme labeled board and the enzyme marker is the enzyme labeled antigen), the gentamycin standard solution, the substrate color solution, the stop solution, the condense washing solution, the condense recovery solution. The invention also discloses the method which includes the process: first to pre-treat the sample, then to detect by the regent box and last to analyze the detecting result. The invention is to detect the gentamycin residue weight in the animal food such as the chicken, chicken liver, pork, pork liver, milk powder, egg and feedstuff. The method is simple, low cost and has high sensitivity, also it is proper for detect the mass sample.

The invention relates to a Chinese-Western compound preparation for treating the infective proventriculitis of a chicken. The Chinese-Western compound preparation is characterized by comprising the following raw materials by weight percentage: 10-30% of elecampane, 5-15% of Chinese atractylodes, 10-20% of cortex magnoliae officinalis, 5-15% of liquorice, 10-20% of hawthorn, 0.3-0.5% of gentamicin,0.5-1% of ranitidine, and the balance of medicated leaven. The preparation method comprises the following steps: comminuting and sieving elecampane, Chinese atractylodes, cortex magnoliae officinalis, liquorice, hawthorn and medicated leaven respectively according to the weight percentage, then sufficiently mixing with gentamicin and ranitidine for 1 h to obtain the Chinese-Western compound preparation. The invention has the advantages that the Chinese-Western medicines are combined to make up the respective shortcomings of the Chinese-Western medicine. When used together, the traditional Chinese medicines have radical treatment for proventriculitis. For the decreased activity of pepsin, the Western medicine can inhibit the gastric acid secretion caused by histamine, pentagastrin and M cholinoceptor agonist. When combined to treat the infective proventriculitis of the chicken, the Chinese-Western medicines have very fast effect and can treat the infective proventriculitis temporarilyand radically; the frequency of administration can be reduced, the focus can be restored and the loss of culturist is reduced.